German Nadezhda, Decker Ann M, Gilmour Brian P, Gay Elaine A, Wiley Jenny L, Thomas Brian F, Zhang Yanan
Research Triangle Institute , Research Triangle Park, North Carolina 27709, United States.
J Med Chem. 2014 Sep 25;57(18):7758-69. doi: 10.1021/jm501042u. Epub 2014 Sep 4.
The recent discovery of allosteric modulators of the CB1 receptor including PSNCBAM-1 (4) has generated significant interest in CB1 receptor allosteric modulation. Here in the first SAR study on 4, we have designed and synthesized a series of analogs focusing on modifications at two positions. Pharmacological evaluation in calcium mobilization and binding assays revealed the importance of alkyl substitution at the 2-aminopyridine moiety and electron deficient aromatic groups at the 4-chlorophenyl position for activity at the CB1 receptor, resulting in several analogs with comparable potency to 4. These compounds increased the specific binding of [(3)H]CP55,940, in agreement with previous reports. Importantly, 4 and two analogs dose-dependently reduced the Emax of the agonist curve in the CB1 calcium mobilization assays, confirming their negative allosteric modulator characteristics. Given the side effects associated with CB1 receptor orthosteric antagonists, negative allosteric modulators provide an alternative approach to modulate the pharmacologically important CB1 receptor.
包括PSNCBAM - 1(4)在内的CB1受体变构调节剂的最新发现引发了人们对CB1受体变构调节的极大兴趣。在此,我们首次对化合物4进行构效关系(SAR)研究,设计并合成了一系列类似物,重点对两个位置进行修饰。钙动员和结合试验中的药理学评估表明,2 - 氨基吡啶部分的烷基取代以及4 - 氯苯基位置的缺电子芳香基团对于CB1受体活性很重要,由此得到了几种与化合物4效力相当的类似物。这些化合物增加了[(3)H]CP55,940的特异性结合,这与之前的报道一致。重要的是,在CB1钙动员试验中,化合物4和两种类似物剂量依赖性地降低了激动剂曲线的最大效应(Emax),证实了它们的负性变构调节剂特性。鉴于CB1受体正构拮抗剂存在的副作用,负性变构调节剂为调节药理学上重要的CB1受体提供了一种替代方法。